Haemonetics (HAE) Cash from Investing Activities (2009 - 2026)

Haemonetics has reported Cash from Investing Activities for 18 years, with the latest figure at -$22.2 million in Q2 2026.

• On a quarterly basis, Cash from Investing Activities rose 32.62% year-over-year to -$22.2 million in Q2 2026; TTM through Jun 2026 was -$168.8 million, a 203.03% decrease from a year earlier, with the FY2026 full-year figure at -$179.5 million, down 10.9% from the prior year.
• Cash from Investing Activities was -$22.2 million for Q2 2026 at Haemonetics, up from -$86.6 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $18.0 million in Q1 2025, with the low at -$268.9 million in Q4 2023.
• Average Cash from Investing Activities over 5 years is -$46.3 million, with a median of -$29.5 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities plunged 812.11% in 2024, then soared 238.17% in 2025.
• Over 5 years, Cash from Investing Activities stood at -$36.5 million in 2022, then sank by 636.81% to -$268.9 million in 2023, then jumped by 93.54% to -$17.4 million in 2024, then plunged by 69.63% to -$29.5 million in 2025, then advanced by 24.54% to -$22.2 million in 2026.
• The last three Cash from Investing Activities figures came in at -$22.2 million (Q2 2026), -$86.6 million (Q1 2026), and -$29.5 million (Q4 2025), per Business Quant data.